Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Low-Dose TAK-475 Trials to Continue; Lifts Stock (Japan)

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceuticals has announced it will continue drug trials of its experimental cholesterol treatment TAK-475. The announcement comes on the heels of a U.S. Food and Drug Administration recommendation that the company stop using high doses of the drug in trials. The decision stemmed from concerns that high doses of the drug may cause liver damage. As a result, the company's stock took a serious downturn, falling 10 percent on Oct. 30. In response, Takeda announced it would remove the 100 mg dose of TAK-475 from trials but continue with the 50 mg dose. Industry insiders say this clarification could put the company's shares back on the rise. (Click here for more - May Require Paid Subscription

You may also be interested in...

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

People On The Move: Appointments At Stada, PGEU, And UK Health Claims Committee

Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts